Despite a relatively light earnings calendar, the upcoming week features a diverse lineup of notable reports across ...

It turns out that the answer was no: Your dog’s genes don’t predict its behavior, at least not in the simplistic way popular doggy DNA tests often claim.

An expanded partnership deal and a $2 billion investment raised confidence in this company's long-term growth prospects.

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Synopsys, Inc. (NASDAQ: SNPS) between December 4, 2024 and September 9, 2025, both dates inclusive (the ...

Synopsys is rated Hold with a $475 price target, reflecting a 10% upside and market-like performance amid premium valuation ...

Dr. Liz Peterson I started working as a doctor in 1981. Back then, I helped children learn lifelong healthy habits — such as brushing their teeth, wearing seat belts and eating good food. I believed ...

This investment serves a strategic purpose, aimed at enhancing the existing partnership between the two firms to advance ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of Synopsys, Inc. (NASDAQ: SNPS) securities between December 4, 2024 and September 9, 2025, both dates ...

Have Medicaid and Medicare? D-SNPs may help support your healthMedicare’s Annual Enrollment Period (AEP) is happening now ...

This article is sponsored by Curana Health. In this Voices interview, Skilled Nursing News speaks with Amy Kaszak, Executive ...

Synopsys stock ought to be on your radar. Here is why – it is presently trading in the support realm, levels from which it has bounced significantly before.

AI darling Nvidia announces a $2.0 billion stake in Synopsys Inc. Here's why that doesn't make SNPS shares worth owning for ...